Thomas Schinecker

CEO, Roche
· tracked since Apr 2026
Calls
1
Win Rate
100.0%
return
+4.0%
Calls 1 2 Posts tracked · 0.0/day Posted today
Calls
7d 0
30d 0
90d 0
Best Calls
RHHBY Long +4.0%
Worst Calls
No live losers yet
Most Mentioned
RHHBY ×2
Recent Calls
RHHBY Long 3 months ago
Win Rate 100% Long 1 Short 0
Win Rate
7d 0%
30d 100%
90d 0%
Average Return +4.0% Long Return +4.0% Short Return -
Average Return
7d -1.9%
30d +1.4%
90d -0.3%
Loading charts...
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
RHHBY Roche Holding AG Roche Holding AG
Long
Apr 23
$51.86
+4.0%
Roche breast cancer drug is blockbuster.
Roche's new breast cancer drug (Giredestrant or similar) has blockbuster potential because it targets hormone receptor positive breast cancer (70% of patients), reduces risk of death/recurrence by over 30%, is well-tolerated, and is the first new hormone treatment in over 20 years. The market overreacted to trial data, and the drug will be one of Roche's biggest medicines.
Pharma & Biotech
YOUTUBE
Showing 1 of 1 calls · sorted by mentions

Thomas Schinecker has 1 trade ideas tracked on Buzzberg across 1 tickers since April 2026. Most covered: RHHBY.